Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MiRNAs expression of prostate cancer with neoadjuvant hormonal therapy

ABSTRACT: The aim of this research was to identify miRNAs that are associated with neoadjuvant hormonal therapy resisitance in prostate cancer.

ORGANISM(S): Homo sapiens

PROVIDER: GSE186994 | GEO | 2022/11/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Prostate Cancer Gene Expression Changes with Neoadjuvant Hormone Therapy

Project description:Men with clinically localized prostate cancer were treated with 0 to 9 months of neoadjuvant hormone suppression prior to prostatectomy. Keywords: microarray, hormone, 9 men with prostate cancer were assigned to neoadjuvant hormone suppression therapy for 3-6, 6, or 0 months.

2008-12-01 | E-GEOD-9983 | biostudies-arrayexpress

Prostate Cancer Gene Expression Changes with Neoadjuvant Hormone Therapy

Project description:Men with clinically localized prostate cancer were treated with 0 to 9 months of neoadjuvant hormone suppression prior to prostatectomy. Keywords: microarray, hormone,

2008-12-01 | GSE9983 | GEO

miRNAs expression of Gleason 3+4 Prostate Cancer

Project description:The aim of this research was to identification of miRNAs that is associated with bone metastasis of gleason 3+4 prostate cancer.

2022-07-01 | GSE155732 | GEO

Modulation of Androgen Receptor Signaling in Hormonal Therapy-Resistant Prostate Cancer Cell Lines

Project description:Prostate epithelial cells depend on androgens for survival and function. In early prostate cancer, besides survival, androgens also regulated tumor growth, which is exploited by androgen ablation/ blockade therapies in metastatic disease. The aim of the present study was to characterize the role of the androgen receptor pathway in prostate cancer progression and to identify potential disease markers. Microarray analysis was used to establish the androgen-regulated gene expression profile, upon stimulation with the synthetic androgen R1881 or the antiandrogen hydroxyflutamide, of the androgen-responsive PC346C cell line and its derivative castration-resistant sublines: PC346DCC (vestigial AR levels), PC346Flu1 (AR overexpression) and PC346Flu2 (T877A mutated AR)

2011-08-05 | GSE22914 | GEO

Modulation of Androgen Receptor Signaling in Hormonal Therapy-Resistant Prostate Cancer Cell Lines

2011-08-04 | E-GEOD-22914 | biostudies-arrayexpress

Neoadjuvant Intense ADT for High Risk Prostate Cancer

Project description:Neoadjuvant Intense ADT for High Risk Prostate Cancer

| PRJNA591228 | ENA

Neoadjuvant Intense ADT for High Risk Prostate Cancer

Project description:Neoadjuvant Intense ADT for High Risk Prostate Cancer

| PRJNA591229 | ENA

Prostate cancer fiber model

Project description:hormonal progression in prostate cancer fiber model Keywords: prostate cancer, hormonal progression, fiber model

2008-07-01 | GSE9666 | GEO

Immune impact of neoadjuvant chemo/radio-therapy in the pancreatic cancer microenvironment

Project description:Pancreatic ductal adenocarcinoma (PDAC) has dismal five-year survival (<9%). We examined the impact of neoadjuvant FOLFIRINOX alone or in combination with radiation therapy (conventional radiotherapy, XRT, or stereotactic body radiotherapy, SBRT) on immunologically relevant genes in the PDAC tumor microenvironment (TME). We hypothesize conventional therapies may induce immune alterations in the TME that can be leveraged to enhance the efficacy of immunotherapy in PDAC. PDAC patients who underwent upfront surgical resection or who received neoadjuvant FOLFIRINOX with or without neoadjuvant radiotherapy followed by surgical resection were selected for study. The expression of 730 immunologically relevant transcripts was quantitated using the Nanostring PanCancer immune profiling panel (Platform GPL19965). This analysis identified189 genes that were differentially expressed at the RNA level on the basis of neoadjuvant therapy. On average specimens were obtained 6.6-17.0 weeks after the conclusion of neoadjuvant therapy, depending on treatment group. These data provide insight into the immunological effects of standard of care neoadjuvant therapy for resectable/borderline-resectable PDAC. This work provides data to guide strategic new combination therapies for pancreatic cancer.

2019-04-09 | GSE129492 | GEO

miRNAs expression of Gleason 3+4 Prostate Cancer

Project description:miRNAs expression of Gleason 3+4 Prostate Cancer

| PRJNA655426 | ENA